NEW YORK, May 4, 2017 /PRNewswire/ --
Stock-Callers.com directs investors' attention to these Drug Manufacturers equities: Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Endo International PLC (NASDAQ: ENDP), Ionis Pharmaceuticals Inc. (NASDAQ: IONS), and Amarin Corp. PLC (NASDAQ: AMRN). Pharmaceutical Manufacturing industry companies manufacture and process pharmaceutical products, and their profitability depends on their ability to discover and market new drugs. You can access our complimentary research reports on these stocks now at:
Shares in Petach Tikva, Israel headquartered Teva Pharmaceutical Industries Ltd saw a drop of 4.33%, ending Wednesday's trading session at $30.72. The stock recorded a trading volume of 11.45 million shares, which was higher than its three months average volume of 8.15 million shares. The Company's shares are trading 6.68% below their 50-day moving average. Moreover, shares of Teva Pharma, which develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide, have a Relative Strength Index (RSI) of 39.32.
On April 27th, 2017, Teva Pharma announced the publication of results from the Phase II/III study ARM-TD (Aim to Reduce Movements in Tardive Dyskinesia) in Neurology®, the medical journal of the American Academy of Neurology. The ARM-TD study evaluated the safety and efficacy of the investigational use of deutetrabenazine (SD-809) compared to placebo in the treatment of moderate to severe tardive dyskinesia. Visit us today and download your complete report on TEVA for free at:
Dublin, Ireland headquartered Endo International PLC's stock dropped 6.52%, closing the day at $10.89 with a total trading volume of 6.87 million shares. The Company's shares are trading 2.93% below their 50-day moving average. Shares of the Company, which develops, manufactures, and distributes pharmaceutical products and devices worldwide, have an RSI of 47.05.
On May 01st, 2017, Endo International announced that Paul Campanelli, President and CEO, is scheduled to present at the UBS Global Healthcare Conference in New York on Tuesday, May 23rd, 2017, at 8:00 a.m. ET. A live webcast and audio archive of the event will be available on the Company's website. The complimentary research report on ENDP can be accessed at:
On Wednesday, shares in Carlsbad, California headquartered Ionis Pharmaceuticals Inc. recorded a trading volume of 752,229 shares. The stock ended the day 1.12% higher at $47.97. The Company's shares have advanced 24.76% in the past month, 8.06% in the previous three months, and 0.29% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 10.98% and 21.05%, respectively. Furthermore, shares of Ionis Pharma, which focuses on developing drugs for patients with severe and rare diseases, have an RSI of 62.32.
On April 26th, 2017, Ionis Pharma announced that it will host a live webcast on Tuesday, May 09th, 2017, at 11:30 a.m. ET to discuss its Q1 2017 financial results and report on pipeline and business progress. The webcast may be accessed on the Company's website. Register for free on Stock-Callers.com and download the PDF research report on IONS at:
Dublin, Ireland-based Amarin Corp. PLC's stock fell 5.05%, finishing yesterday's session at $3.01. A total volume of 4.54 million shares was traded, which was above their three months average volume of 1.48 million shares. The Company's shares have advanced 2.03% in the previous three months. The stock is trading below its 200-day moving average by 2.97%. Additionally, shares of Amarin, which focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the US, have an RSI of 32.25. Get free access to your research report on AMRN at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA